Total Payments
$9,368
2024 Payments
$251.27
Companies
32
Transactions
623
Medicare Patients
13,576
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$9,355 (99.9%)
Education$12.35 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,355 | 621 | 99.9% |
| Education | $12.35 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,343 | 94 | $0 (2024) |
| Amgen Inc. | $1,238 | 52 | $0 (2024) |
| Gilead Sciences, Inc. | $1,057 | 111 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $1,027 | 89 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $598.77 | 33 | $0 (2021) |
| PFIZER INC. | $553.88 | 50 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $517.65 | 29 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $475.33 | 26 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $473.77 | 30 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $368.74 | 22 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $251.27 | 12 | Lexicon Pharmaceuticals, Inc. ($45.10) |
| 2023 | $722.52 | 35 | Merck Sharp & Dohme LLC ($132.92) |
| 2022 | $446.45 | 22 | E.R. Squibb & Sons, L.L.C. ($101.07) |
| 2021 | $435.33 | 24 | Amarin Pharma Inc. ($117.50) |
| 2020 | $365.29 | 20 | Amgen Inc. ($72.35) |
| 2019 | $2,224 | 137 | E.R. Squibb & Sons, L.L.C. ($386.49) |
| 2018 | $2,359 | 189 | Novartis Pharmaceuticals Corporation ($446.12) |
| 2017 | $2,564 | 184 | Gilead Sciences Inc ($736.85) |
All Payment Transactions
623 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $6.70 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 08/08/2024 | iRhythm Technologies, Inc. | ZIO XT Patch (Device), Zio monitor | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 07/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.37 | General |
| Category: Cardiovascular | ||||||
| 07/09/2024 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $31.08 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 06/19/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $24.12 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 04/04/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.02 | General |
| 02/06/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.94 | General |
| 01/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.27 | General |
| Category: Diabetes | ||||||
| 01/18/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $31.51 | General |
| Category: Cardiology | ||||||
| 01/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 01/16/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Not Applicable | ||||||
| 01/03/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 12/20/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.99 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/18/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $19.16 | General |
| Category: Not Applicable | ||||||
| 12/04/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $24.17 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
| 11/20/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $19.92 | General |
| Category: Not Applicable | ||||||
| 11/15/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.21 | General |
| Category: Cardiovascular | ||||||
| 11/07/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/06/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/01/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $18.52 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/30/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/18/2023 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $20.88 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 10/17/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.77 | General |
| 10/17/2023 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $19.21 | General |
| Category: Cardiovascular | ||||||
| 10/16/2023 | Kiniksa Pharmaceuticals, Ltd. | Arcalyst (Drug) | Food and Beverage | Cash or cash equivalent | $22.21 | General |
| Category: Not Applicable | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 3,641 | 4,962 | $1.1M | $295,783 |
| 2022 | 17 | 3,499 | 4,981 | $1.0M | $301,172 |
| 2021 | 22 | 3,458 | 4,856 | $1.0M | $297,369 |
| 2020 | 26 | 2,978 | 3,782 | $870,917 | $263,010 |
Total Patients
13,576
Total Services
18,581
Medicare Billing
$1.2M
Procedure Codes
86
All Medicare Procedures & Services
86 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 768 | 1,259 | $367,469 | $128,729 | 35.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 228 | 230 | $234,490 | $39,195 | 16.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 59 | 59 | $89,665 | $24,953 | 27.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 124 | 124 | $50,406 | $17,022 | 33.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 887 | 1,407 | $86,960 | $16,905 | 19.4% |
| 93245 | Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | Office | 2023 | 41 | 42 | $46,455 | $11,172 | 24.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 187 | 188 | $48,692 | $11,043 | 22.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 88 | 89 | $29,192 | $9,931 | 34.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 75 | 127 | $23,141 | $8,672 | 37.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 908 | 1,110 | $34,414 | $7,376 | 21.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 77 | 77 | $24,639 | $4,281 | 17.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 56 | 57 | $11,075 | $3,621 | 32.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 20 | $7,861 | $2,940 | 37.4% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 16 | 64 | $8,372 | $2,772 | 33.1% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 16 | 16 | $9,016 | $2,624 | 29.1% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 67 | 67 | $16,519 | $2,324 | 14.1% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 14 | 15 | $6,165 | $1,394 | 22.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $2,996 | $829.75 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 751 | 1,342 | $356,314 | $141,281 | 39.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 225 | 229 | $229,916 | $41,052 | 17.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 47 | 47 | $70,453 | $21,151 | 30.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 818 | 1,360 | $81,600 | $16,581 | 20.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 96 | 96 | $38,496 | $13,267 | 34.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 88 | 88 | $28,864 | $10,012 | 34.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2022 | 164 | 164 | $42,476 | $9,913 | 23.3% |
About Dr. Richard Weinstein, M.D
Dr. Richard Weinstein, M.D is a Cardiovascular Disease healthcare provider based in Rockville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073549077.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Weinstein, M.D has received a total of $9,368 in payments from pharmaceutical and medical device companies, with $251.27 received in 2024. These payments were reported across 623 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($9,355).
As a Medicare-enrolled provider, Weinstein has provided services to 13,576 Medicare beneficiaries, totaling 18,581 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 86 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Rockville, MD
- Active Since 06/23/2006
- Last Updated 06/17/2009
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1073549077
Products in Payments
- ELIQUIS (Drug) $1,320
- ENTRESTO (Drug) $1,173
- Repatha (Biological) $847.06
- Ranexa (Drug) $489.30
- LifeVest (Device) $475.33
- PRALUENT (Drug) $424.46
- JARDIANCE (Drug) $419.92
- Corlanor (Drug) $390.46
- BRILINTA (Drug) $335.46
- Edwards SAPIEN 3 Transcatheter Heart Valve (Device) $239.20
- VERQUVO (Drug) $224.02
- Vascepa (Drug) $214.07
- PRALUENT ALIROCUMAB INJECTION (Biological) $196.45
- PRADAXA (Drug) $178.85
- LEQVIO (Drug) $170.78
- XARELTO (Drug) $164.78
- PRALUENT (Biological) $151.94
- CAMZYOS (Drug) $127.35
- NEXLETOL (Drug) $115.27
- Arcalyst (Drug) $102.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Rockville
Dr. Michael Chen, M.d, M.D
Cardiovascular Disease — Payments: $310,148
Cardiovascular Disease $310,148
Dr. Alexander Asser, M.d, M.D
Cardiovascular Disease — Payments: $50,047
Cardiovascular Disease $50,047
Mark Turco, M.d, M.D
Cardiovascular Disease — Payments: $28,326
Cardiovascular Disease $28,326
Dr. Mohsin Ijaz, M.d, M.D
Cardiovascular Disease — Payments: $12,942
Cardiovascular Disease $12,942
Dr. Tushina Jain, Md, MD
Cardiovascular Disease — Payments: $9,272
Cardiovascular Disease $9,272
Dennis Friedman, M.d, M.D
Cardiovascular Disease — Payments: $8,485
Cardiovascular Disease $8,485